Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic Ductal Adenocarcinoma By Ogkologos - May 14, 2026 205 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the RMC-6236-001 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Percentage of Cancer Patients Who Are Eligible for and Respond to... April 15, 2021 Pembrolizumab Combined with Chemoradiotherapy Improves PFS in Women with Newly Diagnosed,... March 27, 2024 News digest – sponge on a string, junk food watershed, prostate... August 1, 2020 No EFS Benefit From Adding Atezolizumab To 1-Year BCG Therapy In... November 17, 2025 Load more HOT NEWS EMA Adopts a Positive Opinion for Dabrafenib for the Treatment of... Making Important Decisions During Cancer: A Survivor’s Story Children’s Hospital Lets Kids Ride Toy Cars Into Surgery To Ease... T-DM1 is Active and Well Tolerated in Patients with HER2-positive Metastatic...
